Our Services / Research

What is NASH?

• ‘Silent’ liver disease. There are usually no symptoms.
• NASH is the inflammatory version that affects 20-30M Americans.
• NASH can progress to cirrhosis, liver failure and liver cancer.
• #1 indication for liver transplant referral in U.S.

Who is at Risk?

• Diabetics have a 1 in 6 risk of having advanced NASH.
• Patients with metabolic syndrome also at risk (HTN, obesity, cholesterol abnormalities).
• Morbid obesity is a key risk factor.

What are the Signs?

• Right sided abdominal pain may be present.
• Liver blood tests may be elevated but are normal in 50% of patients.
• Liver imaging with ultrasound often shows fat liver.
• Fibroscan measures liver stiffness and is key for insights into severity.

What Can Patients Do About this Condition?

Clinical trials may be an important care option for high-risk patients.

Get FibroScan® to understand the health of your liver.

There are currently no FDA approved medicines.

What is FibroScan®?

FibroScan® (FS) is a non-invasive, ultrasound-based procedure that is painless and takes 10 minutes to complete in the clinic setting.

What Does it Measure?

FS measures the stiffness of the liver which correlates with the level of scarring on liver biopsy. Liver scarring is the main predictor of adverse outcomes for this disease.